Clinical trials: oGVHD
Dry Eye
IVIG-eye Drops Treatment for Dry Eye Disease
The main objective of this study is to establish whether patients with Dry Eye Disease are able to safely tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks (primary 'safety and…
- Trial name
- NCT03992482
- Testing
- Intravenous Immune Globulin (IVIG)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sandeep Jain, MD
Dry Eye, Ocular Graft vs Host Disease
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
The objective of this study is to establish whether patients with dry eye disease (DED) are able to tolerate receiving Brimonidine: 0.15% eye drops two times a day for twelve weeks (primary tolerability objective) and to…
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Trial name
- NCT02975557
- Testing
- Brimonidine 0.15%, Brimonidine 0.075%
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sandeep Jain, MD
Graft Versus Host Disease, Ocular Surface Disease
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular Graft Verses Host Disease (oGVHD).
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease
- Trial name
- oGVHD (NCT03591874)
- Testing
- Brimonidine Tartrate
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ocugen
Ocular Graft vs Host Disease, Dry Eye
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
- Trial name
- NCT02702518
- Testing
- rhDNase I, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Illinois Chicago